Details
-
Change Request
-
Resolution: Persuasive
-
Highest
-
At-Home In-Vitro Test Report (FHIR)
-
1.0.0-ballot
-
Orders & Observations
-
Workflow
-
5.1
-
-
Sarah Gaunt / Riki Merrick : 6 - 0 - 3
-
Clarification
-
Non-substantive
Description
The status of the COVID use case is unclear. Is this a generic use case made more realistic by use of the COVID example, or is this a COVID-specific use case? Clarify which portions of this page are "normative" workflow, and which are "colour commentary".
Consider current text compared to:
The at-home in-vitro test report use case starts when a patient purchases an over-the-counter (OTC) test or receives an ordered test kit, for example, a COVID-19 at-home in-vitro test.
Similarly, "the patient is asked questions by the app": do they have to be? Is this a workflow requirement? The whole workflow needs to be recast to identify what here is an example or typical workflow, and what is required from the IG. (Aside, "COVID-19 like symptoms" should be "COVID-19-like symptoms"
Existing Wording:
Workflow (using the COVID-19 At-Home In-Vitro Test Report use case)
The process starts when a patient purchases an over the counter (OTC) test or receives an ordered COVID-19 At-Home In-Vitro Test. The patient interacts with a COVID-19 At-Home In-Vitro Test app. ...
(Comment 18 - imported by: Ron G. Parker)
Attachments
Issue Links
- is voted on by
-
BALLOT-39677 Affirmative - Elliot Silver : 2022-Sep-FHIR IG HOME IV REPORT R1 STU
- Balloted
-
BALLOT-40670 Affirmative - Sheridan Cook : 2022-Sep-FHIR IG HOME IV REPORT R1 STU
- Balloted